Related Experiment Video
Updated: Aug 17, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Development of curative therapies for sickle cell disease
Yvette C Tanhehco1, Ghazala Nathu2, Ljiljana V Vasovic3
1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Insights
Recent Sickle Cell Disease (SCD) treatments, including new drugs and stem cell transplants, have improved patient outcomes. Gene therapy offers a promising potential cure, requiring expert multidisciplinary care for effective SCD management.
Area of Science:
- Hematology
- Genetics
- Pharmacology
Background:
- Sickle Cell Disease (SCD) management has advanced, improving survival and quality of life.
- Current treatments include disease-modifying drugs and hematopoietic stem cell transplantation (HSCT).
- HSCT offers a cure but is limited by donor availability.
Purpose of the Study:
- To review recent advancements in SCD management.
- To highlight emerging curative therapies like gene therapy.
- To emphasize the need for multidisciplinary expertise in SCD care.
Main Methods:
- Review of recent literature on SCD therapies.
- Analysis of drug efficacy and transplantation outcomes.
- Discussion of gene therapy approaches and clinical trial progress.
Main Results:
- Disease-modifying drugs (e.g., hydroxyurea, L-glutamine, voxelotor, crizanlizumab) reduce SCD complications.
- Expanded donor options for HSCT (cord blood, haploidentical) increase accessibility.
- Gene therapy trials show promising efficacy for SCD cure.
Conclusions:
- SCD management has significantly improved with new drug therapies and expanded transplantation options.
- Gene therapy represents a highly promising curative approach for SCD.
- Optimal SCD treatment necessitates a multidisciplinary expert team.
Abstract:
Recent advances in managing Sickle Cell Disease (SCD) significantly improved patient survival and quality of life. Disease-modifying drug therapies such as hydroxyurea, L-glutamine, voxelotor, and crizanlizumab reduce pain crises and severe complications. Allogeneic hematopoietic stem cell transplantation using matched-sibling donors is currently the only standard curative option; however, only a small proportion of patients have such donors. Cord blood and haploidentical transplantation with a modified conditioning regimen have expanded the allogeneic donor pool, making the therapy available to more patients. Gene therapy is a promising cure that is currently undergoing clinical trials and different approaches have demonstrated efficacy. Multidisciplinary expertise is needed in developing the best treatment strategy for patients with SCD.
More Related Videos
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
iPS Cell Differentiation
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Gene Therapy
Regulation of Hematopoietic Stem Cells
Stem Cell Culture